<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">EXCLI J</journal-id><journal-id journal-id-type="iso-abbrev">EXCLI J</journal-id><journal-id journal-id-type="publisher-id">EXCLI J</journal-id><journal-title-group><journal-title>EXCLI Journal</journal-title></journal-title-group><issn pub-type="epub">1611-2156</issn><publisher><publisher-name>Leibniz Research Centre for Working Environment and Human Factors</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28507473</article-id><article-id pub-id-type="pmc">5427479</article-id><article-id pub-id-type="publisher-id">2016-846</article-id><article-id pub-id-type="doi">10.17179/excli2016-846</article-id><article-id pub-id-type="publisher-id">Doc278</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ekhlasi</surname><given-names>Golnaz</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zarrati</surname><given-names>Mitra</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Agah</surname><given-names>Shahram</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hosseini</surname><given-names>Agha Fatemeh</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hosseini</surname><given-names>Sharieh</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Shidfar</surname><given-names>Shahrzad</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Soltani Aarbshahi</surname><given-names>Seyed Soroush</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Razmpoosh</surname><given-names>Elham</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Shidfar</surname><given-names>Farzad</given-names></name><xref ref-type="corresp" rid="COR1">*</xref><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A8">8</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran</aff><aff id="A2"><label>2</label>Colorectal Research Center; Iran University of Medical Sciences, Tehran, Iran</aff><aff id="A3"><label>3</label>Department of Math and Statistics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran</aff><aff id="A4"><label>4</label>Department of Applied Chemistry, Faculty of Pharmaceutical Chemistry, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran (IAUPS)</aff><aff id="A5"><label>5</label>Internist, Worcester Memorial Hospital, University of Massachusetts, Worcester, Massachusetts, U.S.A</aff><aff id="A6"><label>6</label>Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</aff><aff id="A7"><label>7</label>Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</aff><aff id="A8"><label>8</label>Iran National Science Foundation, Tehran, Iran</aff><author-notes><corresp id="COR1">*To whom correspondence should be addressed: Farzad Shidfar, Department of Nutrition, School of Public Health, Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran; Tel: +98 2186704711, Fax: +98 2186704711, E-mail: <email>farzadshidfar@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>16</volume><fpage>278</fpage><lpage>290</lpage><history><date date-type="received"><day>18</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Ekhlasi et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>) You are free to copy, distribute and transmit the work, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="http://www.excli.de/vol16/Shidfar_20032017_proof.pdf">This article is available from http://www.excli.de/vol16/Shidfar_20032017_proof.pdf</self-uri><abstract><p>Non-alcoholic fatty liver disease (NAFLD) has been suggested to be well correlated with altered blood pressure. This study was conducted to determine the effects of symbiotic and vitamin E supplementation on blood pressure and inflammatory indices of patients with NAFLD. This randomized, double-blind, placebo-controlled trial was performed among 60 NAFLD patients aged 25 to 64 years old. Participants were randomly divided into four groups to receive a 400 IU alpha-tocopherol and 2 &#x000d7; 10<sup>8</sup> CFU/g symbiotic supplement for 8 weeks. The anthropometric parameters, systolic blood pressure (SBP) and diastolic blood pressure (DBP), serum malondialdehyde (MDA), nitric oxide (NO) and tumor necrosis factor &#x003b1; (TNF&#x003b1;) were assessed at baseline and after 8 weeks of intervention. After 8 weeks of intervention, combined symbiotic and alpha-tocopherol, symbiotic and alpha-tocopherol alone administration, compared with the placebo, resulted in significant decreases in SBP (-17.07&#x000b1;2.1, -16.07&#x000b1;3.56, -1.73&#x000b1;2.25 and -1.55&#x000b1;3.01 mmHg, P=0.01), serum MDA (-1.19&#x000b1;0.5, -0.12&#x000b1;0.65, 0.14 &#x000b1; 0.64 and 0.16&#x000b1;0.34 nmol/mL, P&#x0003c;0.001), serum TNF&#x003b1; (-15.62&#x000b1;13.93, -9.24&#x000b1;7.12, -11.44 &#x000b1; 15.47 and 3.01&#x000b1;1.71 pg/ml, P&#x0003c;0.001) concentrations. A significant decrease in serum AST (-11.36&#x000b1;4.52, -7.43&#x000b1;8.58, -5.93&#x000b1;6.61 and 2.5&#x000b1;5.75 &#x003bc;mol/L, P &#x0003c;0.001), ALT (-12.79&#x000b1;3.65, -3.66&#x000b1;6.81, -6.54&#x000b1;7.66 and 4.16&#x000b1;3.43 &#x003bc;mol/L, P &#x0003c;0.001) and ALP (-26.8&#x000b1;11.1, -4.56&#x000b1;9.22, -14.48&#x000b1;12.22 and 5.19&#x000b1;2.64 &#x003bc;mol/L, P &#x0003c;0.001) was seen. Variations in DBP and serum NO concentration were not significant. Alpha-tocopherol and symbiotic supplementation among patients with NAFLD resulted in decreased SBP, serum MDA, TNF&#x003b1; levels and enzymes liver; however, they did not affect DBP and serum NO concentration.</p></abstract><kwd-group><kwd>symbiotic</kwd><kwd>alpha-tocopherol</kwd><kwd>blood pressure</kwd><kwd>nitric oxide</kwd><kwd>NAFLD</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>NAFLD is one of the most common chronic liver diseases in the world today, occurring when fat is deposited (steatosis) in the liver (Wong et al., 2014[<xref rid="R46" ref-type="bibr">46</xref>]). The prevalence of NAFLD is reported to be 14-30 % of the general population in different parts of the world (Adams and Angulo, 2006[<xref rid="R1" ref-type="bibr">1</xref>]); this condition affects 21.5-31.5 % of adult's population in Iran (Jamali et al., 2008[<xref rid="R19" ref-type="bibr">19</xref>]). Various factors including obesity, insulin resistance, hypertriglyceridemia, hypertension, protein-calorie malnutrition, rapid weight loss, the use of medications such as glucocorticoids and metabolic factors are reported as contributors to the increased risk of NAFLD (Adams and Angulo, 2006[<xref rid="R1" ref-type="bibr">1</xref>]).</p><p>Not only insulin resistance and oxidative stress status are considered as roots of non-alcoholic fatty liver disease, but also intestinal flora is responsible for NAFLD. Small intestinal bacterial overgrowth (SIBO) is proposed to be responsible for the inflammation occurred through the production of cytokine, yet the exact mechanism is still unknown (Medina et al., 2004[<xref rid="R26" ref-type="bibr">26</xref>]). Some particular risk factors such as obesity, diabetes mellitus (insulin resistance) and dyslipidemia can be strongly connected with NAFLD. </p><p>Recent literature supports the role of a gut-liver interaction in the pathogenesis of portal hypertension as a novel therapeutic focus; the prevailing hypothesis is that bacterial translocation stimulates the release of pro-inflammatory cytokines and the activation of the vasodilator nitric oxide results in a more pronounced deterioration of the baseline hyperdynamic circulatory state (Chin-Dusting et al., 1997[<xref rid="R9" ref-type="bibr">9</xref>]; Wiest et al., 1999[<xref rid="R44" ref-type="bibr">44</xref>]).</p><p>Subjects with NAFLD and elevated liver enzyme levels are at an increased risk of developing blood pressure and metabolic syndrome due to the oxidative stress status; in fact, decreased level of antioxidants in patients with NAFLD has effects on the measures of blood pressure. TNF&#x003b1; is also responsible for the pathogenesis of NAFLD via effecting on mitochondrial radical formation which might finally lead to cell death (Tilg and Diehl, 2000[<xref rid="R39" ref-type="bibr">39</xref>]; Peralta and Rosello-Catafau, 2004[<xref rid="R28" ref-type="bibr">28</xref>]); on the other hand, intestinal flora has also a significant role in production of cytokines (Solga and Diehl, 2003[<xref rid="R36" ref-type="bibr">36</xref>]).</p><p>Recently, it has been suggested that immoderate proliferation of pathogenic intestinal bacteria is inhibited by probiotics; it has been well attested by animal and human researches that probiotic bacteria could control blood pressure due to its antihypertensive effects (Reid et al., 2009[<xref rid="R32" ref-type="bibr">32</xref>]). Some investigators have evidenced that probiotic bacteria may control blood pressure (Myhre et al., 2011[<xref rid="R27" ref-type="bibr">27</xref>]; van Baarlen et al., 2011[<xref rid="R42" ref-type="bibr">42</xref>]; Ebel et al., 2014[<xref rid="R11" ref-type="bibr">11</xref>]). This mechanism of action of probiotics is multifactorial, related to their impact on intestinal microflora, cytokine production and maintenance of the epithelial barrier (Boirivant and Strober, 2007[<xref rid="R6" ref-type="bibr">6</xref>]).</p><p>Further, antioxidant agents have been proposed as a potentially effective treatment; vitamin E is a potent antioxidant compound that has been tested in pediatric NAFLD due to the absence of side effects. Conflicting results have been reported in clinical trials, among both children and adults (Lavine, 2000[<xref rid="R23" ref-type="bibr">23</xref>]; Harrison et al., 2003[<xref rid="R17" ref-type="bibr">17</xref>]; Vajro et al., 2004[<xref rid="R40" ref-type="bibr">40</xref>]).</p><p>Despite these findings, to the best of our knowledge, there are no reports regarding the favorable synergistic effects of the symbiotic and alpha-tocopherol supplementation on biomarkers of inflammation, oxidative stress and blood pressure in NAFLD patients. We hypothesized that the combined supplementation with symbiotic and alpha-tocopherol might help NAFLD patients to control their blood pressure; the current trial was to assess the effects of some species of probiotics along with alpha-tocopherol supplements on biomarkers of inflammation, oxidative stress and blood pressure in NAFLD patients.</p></sec><sec sec-type="materials"><title>Materials</title><sec><title>Participants</title><p>This randomized double-blind clinical trial was performed in Tehran, Iran, during 2012 to 2013 among 60 NAFLD patients (48 men and 12 women) aged 25 to 64 years old, who were recruited from Hazrat-e-Rasoul Medical Complex (Colorectal Research Center) in Tehran, Iran. </p></sec><sec><title>Ethics statements</title><p>This study was conducted in accordance with the Declaration of Helsinki and informed consent was obtained from all participants. The research was approved by the ethics committee of IUMS and was recorded in the Iranian website for registration of clinical trials (www.irct.ir: IRCT201111082709N22).</p></sec><sec><title>Study design</title><p>All eligible patients with NAFLD were recruited (Figure 1<xref ref-type="fig" rid="F1">(Fig. 1)</xref>). The diagnosis of NAFLD was based on hepatic ultrasonography (grade 1 to 3), which was associated with the elevation of alanine aminotransferase (ALT) concentration (30 mg/dL) for 6 months before the study initiation and at the time of randomization. The eligibility criteria included females and males with a body mass index (BMI) ranging from 25 to 35 kg/m<sup>2</sup>.</p><p>Exclusion criteria comprising any pathologic conditions affecting liver as viral hepatitis, alcohol consumption, hypothyroidism, Wilson disease, acute systemic disease, cystic fibrosis, coeliac disease and alpha-1-antitrypsin deficiency as well as a history of cancer, metabolic disorders, cardiovascular disease, autoimmune diseases and drug or alcohol abuse. Diabetes mellitus, pregnancy, lactation, menstruation at the time of blood sampling, infectious diseases during the study, using non-steroidal anti-inflammatory drugs, antibiotics, and probiotics and food supplements prior to the enrolment of the study were also considered as exclusion criteria.</p><p>Physical examinations, medical history, diet and physical activity level of each patient were assessed at the beginning of the study. Subjects were asked not to consume any probiotic containing food, yogurt, or its products during an initial 2 week run-in period before the study. They were also asked not to consume other probiotic products during the intervention. At the end of the run-in period, eligible patients were randomly assigned to one of the named groups. Symbiotic Group (n=15) who consumed symbiotic and alpha-tocopherol-like placebo capsule, alpha-tocopherol group (n=15) who received alpha-tocopherol and symbiotic-like placebo, symbiotic + alpha-tocopherol group (n=15) who consumed symbiotic and alpha-tocopherol supplementation and the final 15 patients were given symbiotic-like placebo and an alpha-tocopherol-like placebo supplementation as control group.</p></sec><sec><title>Intervention</title><p>Each symbiotic capsule [Protexin; Probiotics International Ltd., Lopen Head, Somerset, United Kingdom] contained <italic>Lactobacillus casei, Lactobacillus rhamnosus, Stretococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus bulgaricus</italic> and prebiotic (fructooligosaccharide). The concentration of each probiotic strain was 2 &#x000d7; 10<sup>8</sup> CFU/g per capsule. Patients were asked to consume 2 symbiotic capsules per day (each capsule contained 1 g) orally after the main meal. Two identical-appearing placebo capsules [corn starch, Zahravi Pharmaceutical Co, Tabriz, Iran] were taken daily by participants assigned to either the placebo or the alpha-tocopherol group. Justification for choosing this dosage was based on the earlier study (Aller et al., 2011[<xref rid="R3" ref-type="bibr">3</xref>]). Alpha-tocopherol [RRR-&#x003b1;-tocopherol, Zahravi Pharmaceutical Co, Tabriz, Iran] at a daily dosage of 400 IU and similar appearing placebo were administered orally. This chosen dose of alpha-tocopherol was similar to previous study in NAFLD patients (Chalasani et al., 2012[<xref rid="R8" ref-type="bibr">8</xref>]).</p><p>Randomization was carried out according to Balanced Block Randomization procedure while participants, nutrition specialists, and outcome assessors were all blinded to the interventions into which the individuals were allocated. This study was granted by Iran National Science Foundation.</p></sec><sec><title>Treatment adherence</title><p>Compliance was monitored by phone calls weekly and verified using capsule counts (number of capsules left in the capsule bottle at the end of the study).</p></sec><sec><title>Assessment of anthropometric measures</title><p>Weight (Seca, Hamburg, Germany) was measured at study baseline and after 8 weeks of intervention. Height was measured using a non-stretched tape measure (Seca, Hamburg, Germany). BMI was calculated using the height and weight measurements (weight in kg/[height in meters]<sup>2</sup>).</p></sec><sec><title>Assessment of outcomes</title><p>The primary objective was a reduction in SBP and DBP in NAFLD patient with daily alpha-tocopherol and symbiotic supplementation; secondary objectives were changes in serum nitric oxide, MDA and serum TNF&#x003b1;. Levels of serum TNF&#x003b1; were measured using enzyme linked immunosorbent assay kits (eBioscience, USA). Plasma MDA levels were determined by thiobarbituric acid reactive substance spectrophotometric test (Janero, 1990[<xref rid="R20" ref-type="bibr">20</xref>]). Plasma nitrite/nitrate, taken as an index of nitric oxide (NO) concentrations, was determined using the Giess method which was modified by Tatsch et al. (2011[<xref rid="R38" ref-type="bibr">38</xref>]).</p></sec><sec><title>Randomization</title><p>Randomization assignment was performed using computer-generated random numbers. Randomization and allocation were blinded to the researchers and participants until the final analyses were completed. The randomized allocation sequence as well as enrolling participants and allocating them to interventions were conducted by a trained staff at the department of nutrition.</p></sec><sec><title>Statistical analysis</title><p>To examine the normal distribution of variables, we used Kolmogorov-Smirnov test. The analyses were conducted based on intention-to-treat (ITT) approach. One-way analysis of variance (ANOVA) was used to detect differences in general characteristics, dietary intakes, chemical biomarkers and blood pressure at the study initiation between the four groups. A Pearson &#x003c7;2 test was used for comparison of categorical variables. Repeated measure ANOVA was used to determine the effects of symbiotic plus alpha-tocopherol administration on blood pressure and the used biomarkers, we adjusted the analysis for biochemical parameters, age and BMI, to assess their confounding effects. P values less than 0.05 were considered as statistically significant. All statistical analyses were done using the Statistical Package for Social Science version 17 (SPSS Inc., Chicago, Ill., USA).</p></sec></sec><sec sec-type="results"><title>Results</title><p>The raw data are provided as an attachment (). 65 NAFLD patients were recruited in the study at baseline; however, 2 subjects were excluded as one of them was not a local resident (n = 1) and the other had a sudden heart attack during the study (n = 1); furthermore, in the symbiotic group, 2 subjects [death (1 = 3)], s (n = 1)] were excluded from the alpha-tocopherol group, due to personal reason and death. Moreover, 2 persons [death (n = 1) and withdrawal due to personal reasons (n = 1)] were excluded from the placebo group. Finally, 60 participants [symbiotic (n = 15), alpha-tocopherol (n = 15), symbiotic plus alpha-tocopherol (n = 15) and placebo (n = 15)] completed the trial. However, as the analysis was performed based on intention-to-treat principle, all 60 patients (15 in each group) were included in the final analysis. No side effects were recorded following the administration of symbiotic, alpha-tocopherol, and joint symbiotic and alpha-tocopherol supplements in patients with NAFLD throughout the study.</p><p>There were no initial differences in the mean measures of age (44 &#x000b1; 20 y, P = 0.09), height, body weight, SBP, DBP and BMI between all the groups. Table 1<xref ref-type="fig" rid="T1">(Tab. 1)</xref> summarizes the selected data of patients at the beginning and the end of the study. </p><p>In addition, mean values of height, weight and BMI were not statistically different between the four groups after the treatment period.</p><p>According to the 3-day dietary records that were obtained throughout the intervention, no statistically significant differences were seen between the four groups in terms of macro- and micro-nutrient intakes (Table 2<xref ref-type="fig" rid="T2">(Tab. 2)</xref>).</p><p>Joint supplementation with symbiotic and alpha-tocopherol had no significant effects on DBP and serum NO levels. After 8 weeks of intervention, all three groups of alpha-tocopherol only, individual symbiotic, and combined symbiotic and alpha-tocopherol experienced a significant improvements in SBP compared with the placebo group (P=0.01); however, improvements were much greater in the individual symbiotic (-16.07&#x000b1;3.56 mmHg) and combined symbiotic and alpha-tocopherol (-17.07&#x000b1;2.1 mmHg) groups compared with alpha-tocopherol group alone (-1.73&#x000b1;2.25 mmHg) (Table 1<xref ref-type="fig" rid="T1">(Tab. 1)</xref>).</p><p>A significant decrease in serum MDA was shown in all intervention groups (alpha-tocopherol: 0.14&#x000b1;0.64; symbiotic: -0.12&#x000b1;0.65; combined group: -1.19&#x000b1;0.5 and placebo: 0.16&#x000b1;0.34 nmol/mL, P&#x0003c;0.001). Reduction in the levels of TNF&#x003b1; among individuals taking co-supplements of symbiotic and alpha-tocopherol, was greater in comparison to the other groups (alpha-tocopherol: -11.44&#x000b1; 15.47; symbiotic: -9.24&#x000b1;7.12; combined group: -15.62&#x000b1;13.93 and placebo: 3.01&#x000b1;1.71 pg/mL, P=0.001).</p><p>Furthermore, a significant decrease in serum AST level was seen among both individual and combined intervention with symbiotic and alpha-tocopherol groups (combined group: -11.36&#x000b1;4.52; alpha-tocopherol: -5.93&#x000b1; 6.61; symbiotic: -7.43&#x000b1;8.58; and placebo: 2.5&#x000b1;5.75&#x003bc;mol/L, respectively, P&#x0003c;0.001), ALT (combined group: -12.79&#x000b1;3.65; alpha-tocopherol: -3.66&#x000b1;6.81; symbiotic: -6.54&#x000b1; 7.66; and placebo: 4.16&#x000b1;3.43 &#x003bc;mol/L, respectively, P&#x0003c;0.001) and ALP (combined group: -26.8&#x000b1;11.1; alpha-tocopherol: -4.56&#x000b1;9.22; symbiotic: -14.48&#x000b1;12.22; and placebo: 5.19&#x000b1;2.64 &#x003bc;mol/L, respectively, P&#x0003c;0.001) (Table 3<xref ref-type="fig" rid="T3">(Tab. 3)</xref>).</p><p>When the analyses were adjusted for baseline values including biochemical parameters, age and BMI, significant changes in our findings were observed except for NO (P = 0.82) and DBP (P = 0.82) levels (Table 4<xref ref-type="fig" rid="T4">(Tab. 4)</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>This study demonstrated that administration of symbiotic and alpha-tocopherol supplements for 8 weeks among patients with NAFLD had beneficial effects on SBP, liver enzymes, serum TNF&#x003b1; and MDA levels compared with the control group, while they did not affect DBP and serum NO levels. To the best of our knowledge, this is the first study evaluating the favorable synergistic effects of symbiotic and alpha-tocopherol supplementation on blood pressure and biomarkers of inflammation and oxidative stress among patients with NAFLD. </p><p>Our study revealed that consumption of 2 &#x000d7; 10<sup>8</sup> CFU/g symbiotic and 400 IU of alpha-tocopherol for 8 weeks among patients with NAFLD compared with the placebo group led to significant reductions in SBP.</p><p>In line with our findings, in a study by Yamamoto et al.(Yamamoto et al., 1994[<xref rid="R47" ref-type="bibr">47</xref>]) oral administration of <italic>Lactobacillus acidophilus</italic> yoghurt in spontaneously hypertensive rats (SHR) has shown that milk fermented with <italic>L. heveticus </italic>and casein hydrolysates, which were produced by this organisms, have anti-hypertensive activity. Cell wall polysaccharide-glycoprotein complexes of <italic>L. casei</italic> have also been reported to have antihypertensive activity in SHR and hypertensive rats (Sawada et al., 1990[<xref rid="R35" ref-type="bibr">35</xref>]; Furushiro et al., 1993[<xref rid="R15" ref-type="bibr">15</xref>]), it has been suggested that probiotic therapy may decrease blood pressure in cirrhosis via reducing intestinal permeability and bacterial translocation, decreasing the exposure of the immune system to intestinal bacteria and bacterial products and thereby reducing the inflammatory cytokines. Endotoxin is hypothesized to be originated from the intestinal tract as a result of increased gut permeability and bacterial translocation; in the study of Tandon et al. (2009[<xref rid="R37" ref-type="bibr">37</xref>]), there was a trend in the reduction of plasma endotoxin levels which was resulted by probiotic therapy, suggesting that probiotics would be effective in enhancing the gut barrier function, but the magnitude of change might have not been detectable by the intestinal permeability technique utilization.</p><p>Data on diastolic blood pressure needs to be interpreted with caution, and future studies with larger sample size would hopefully provide valuable information concerning this topic.</p><p>Findings from this study have shown that consumption of the symbiotic and alpha-tocopherol for 8 weeks among NAFLD patients significantly reduced serum TNF&#x003b1; compared with the placebo.</p><p>The beneficial effects of some probiotic species on serum TNF&#x003b1; concentration among patients with NAFLD have previously been evaluated (Aller et al., 2011[<xref rid="R3" ref-type="bibr">3</xref>]; Vajro et al., 2011[<xref rid="R41" ref-type="bibr">41</xref>]; Malaguarnera et al., 2012[<xref rid="R25" ref-type="bibr">25</xref>]). Supporting our study, a study by Malaguarnera et al. (2012[<xref rid="R25" ref-type="bibr">25</xref>]) reported significant decreases in serum TNF&#x003b1; levels after 24 weeks of intervention with <italic>Bifidobacterium longum </italic>and fructo-oligosaccharides among patients with non-alcoholic steatohepatitis. This protective effect is as a result of reduced hepatic exposure to intestinal products, such as lipopolysaccharides (LPS), which induced the release of TNF&#x003b1; from hepatic macrophage. TNF&#x003b1; is a cytokine that promotes cell death in the liver and increases inflammation and thus blood pressure (Solga and Diehl, 2003[<xref rid="R36" ref-type="bibr">36</xref>]).</p><p>It is logical to assume that similar effects of intestinal flora and NAFLD also exist, since TNF&#x003b1; is the key mediator of inflammation and so hypertension in this disease. Currently, there are two mechanisms in which intestinal flora may increase the hepatic oxidative stress and thus the blood pressure; the first is the increased endogenous ethanol production, and the second is the direct activation of inflammatory cytokines in luminal epithelial cells, non-parenchymal liver cells (macrophages) or both of them via releasing LPS, which may activate the production of TNF&#x003b1; in Kupffer cells and thus induce hepatic inflammation, oxidative stress and high blood pressure (Aqel and DiBaise, 2015[<xref rid="R4" ref-type="bibr">4</xref>]). </p><p>High amounts of bacterial DNA and their derivatives induce the production of TNF&#x003b1;, IL-2, IL-6, IL-12 (Frances et al., 2004[<xref rid="R13" ref-type="bibr">13</xref>]; Frances et al., 2005[<xref rid="R14" ref-type="bibr">14</xref>]). In the liver, the extensive attachment of LPS to CD4/TLR4 induces high amounts of LPS-binding protein (Albillos et al., 2003[<xref rid="R2" ref-type="bibr">2</xref>]). Inefficient local immunity was demonstrated in liver disease, particularly in patients with cirrhosis; the potent mechanism is a depression in the activity of kupffer cells and the reticular endothelium system which plays a significant role in the defense against infected bacteria (Rimola et al., 1984[<xref rid="R33" ref-type="bibr">33</xref>]). Our findings differ from previous study due to TNF&#x003b1; levels; precisely, in the study by Tandon et al. (2009[<xref rid="R37" ref-type="bibr">37</xref>]) small increase observed in serum TNF&#x003b1;, was an unexpected finding after the probiotic therapy which could be anticipated to reduce the levels of pro-inflammatory mediators; although there were no significant adverse events of probiotic administration in patients with liver disease either in the current study or in previous ones (Rayes et al., 2002[<xref rid="R30" ref-type="bibr">30</xref>], 2005[<xref rid="R31" ref-type="bibr">31</xref>]; Lata et al., 2007[<xref rid="R21" ref-type="bibr">21</xref>]) there is a probability that an increase in the production of TNF&#x003b1; may represent harmful effects. There are two relevant subjects in this context, different types of probiotic species used in these studies and small sample size. </p><p>In line with Loguercio et al. (2005[<xref rid="R24" ref-type="bibr">24</xref>]), the current study revealed that simultaneous supplementation of 400 IU alpha-tocopherol and symbiotic had synergistic effect on the reduction of serum MDA in NAFLD patients; the mentioned study demonstrated that supplementation of probiotic <italic>VSL#3</italic> in NAFLD patients could significantly improve plasma levels of MDA; another study has demonstrated that supplementation with <italic>Lactobacillus casei </italic>in the hyperlipidemic rats, decreased the levels of MDA (Zhang et al., 2010[<xref rid="R48" ref-type="bibr">48</xref>]).</p><p>Ejtehad et al. (2012[<xref rid="R12" ref-type="bibr">12</xref>]) showed that consumption of 300 g/d of probiotic yogurt containing <italic>Lactobacillus acidophilus La5</italic> and <italic>Bifidobacterium lactis Bb12</italic> could significantly decrease serum MDA concentration in type 2 diabetic patients; moreover, Daga et al. (2003[<xref rid="R10" ref-type="bibr">10</xref>]) found an inverse association between 400 IU/d vitamin E supplementation and serum MDA among COPD patients.</p><p>Oxidative stress is now believed to be an important factor in the development of hypertension in non-alcoholic fatty liver disease; increased blood pressure is found to be associated with NAFLD in patients with increased alanine transaminase concentrations (Lau et al., 2010[<xref rid="R22" ref-type="bibr">22</xref>]). Although, the mechanism explaining the association between NAFLD and increased blood pressure is still unclear, it has recently been demonstrated that there is a general thickening of the left ventricular wall and lipid peroxidation in NAFLD (Cassidy et al., 2015[<xref rid="R7" ref-type="bibr">7</xref>]); increased wall thickness due to the oxidative stress is associated with reduced longitudinal fiber shortening which is indicative for left ventricular hypertrophy (Hollingsworth et al., 2012[<xref rid="R18" ref-type="bibr">18</xref>]); this hypertrophy of the cardiac wall may also lead to the increased ventricular strain that is seen in NAFLD, which both finally affect the endocardium and entire wall as a result of the altered geometry (reduced radius).</p><p>This study assessed the supplementation of both symbiotic and alpha-tocopherol on serum NO concentration in people with NAFLD; although the plasma NO levels were increased in all intervention groups, the changes were not significant. The beneficial effects of vitamin E supplementation on serum NO and so blood pressure among patients with metabolic syndrome have been previously evaluated (Vivekananthan et al., 2003[<xref rid="R43" ref-type="bibr">43</xref>]; Rodrigo et al., 2008[<xref rid="R34" ref-type="bibr">34</xref>]).</p><p>Vasodilation in response to the increased flow is a function of the normal endothelium through the secretion of NO; loss of normal endothelial function results in impaired vasodilation and increased blood pressure and may be a common pathway to hypertension (Giles et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>]). Antioxidants such as vitamin E have beneficial effects on controlling hypertension and reducing oxidative damage which result in a reduction in blood pressure levels (Baradaran et al., 2014[<xref rid="R5" ref-type="bibr">5</xref>]).</p><p>NO plays an important role in regulating systemic vascular resistance, arterial relaxation, and dispensability; collectively, these actions reduce cardiac hemodynamic load, which thereby reduce myocardial hypertrophy and left ventricular dysfunction and finally protect target organs (Raij, 2001[<xref rid="R29" ref-type="bibr">29</xref>]; Wilkinson et al., 2004[<xref rid="R45" ref-type="bibr">45</xref>]). Thus, NO plays a major role in maintaining and regulating blood pressure.</p><p>The strengths of the current study were the double blinding methods without any dropout rates. This study had some limitations, as well first of all, duration of intervention was relatively short. Moreover, we did not evaluate the effects of symbiotic and vitamin E supplementation on other factors related to blood pressure including rennin and angiotensin levels.</p><p>In addition, because of the budget limitations, we could not assess other biomarkers of systemic inflammation including interleukin 1(IL-1) and IL-6 as well as the biomarkers of oxidative stress such as catalase and superoxide dismutase in NAFLD patients. Future studies with crossover design, longer duration of intervention and larger sample size are needed to confirm the validity of our findings.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Overall, administration of 400 IU alpha-tocopherol and symbiotic supplements containing <italic>Lactobacillus casei, Lactobacillus rhamnosus, Stretococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, </italic>and<italic> Lactobacillus bulgaricus</italic> for 8 weeks among patients with NAFLD had beneficial effects on systolic SBP, MDA and TNF&#x003b1; but did not affect DBP and serum NO levels compared with the control group. Findings of the current study suggest that simultaneous supplementation of vitamin E and symbiotic may confer advantageous therapeutic outcomes for patients with NAFLD.</p></sec><sec><title>Compliance with ethical standards</title><p><bold>Funding</bold><bold><italic>: </italic></bold>This study was funded by Iran national science foundation (grant number: 90005246).</p><p><bold>Conflict of interest: </bold>The authors declare that they have no conflict of interest.</p><p><bold>Ethical approval:</bold> All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p><p><bold>Informed consent:</bold> Informed consent was obtained from all individual participants included in the study.</p></sec><sec><title>Acknowledgements</title><p>The authors thank the participants in the study for their important contributions.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><caption><title>Raw data</title></caption><media mimetype="application" mime-subtype="application/pdf" xlink:href="EXCLI-16-278-s-001.pdf" xlink:type="simple" id="d35e596" position="anchor"/></supplementary-material></sec></body><back><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal">
<person-group><name><surname>Adams</surname><given-names>LA</given-names></name><name><surname>Angulo</surname><given-names>P</given-names></name></person-group>
<article-title>Treatment of non-alcoholic fatty liver disease</article-title>
<source>Postgrad Med J</source>
<year>2006</year>
<volume>82</volume>
<issue>967</issue>
<fpage>315</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="pmid">16679470</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal">
<person-group><name><surname>Albillos</surname><given-names>A</given-names></name><name><surname>de la Hera</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>M</given-names></name><name><surname>Moya</surname><given-names>JL</given-names></name><name><surname>Calleja</surname><given-names>JL</given-names></name><name><surname>Monserrat</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement</article-title>
<source>Hepatology (Baltimore, Md)</source>
<year>2003</year>
<volume>37</volume>
<fpage>208</fpage>
<lpage>217</lpage>
</element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal">
<person-group><name><surname>Aller</surname><given-names>R</given-names></name><name><surname>De Luis</surname><given-names>DA</given-names></name><name><surname>Izaola</surname><given-names>O</given-names></name><name><surname>Conde</surname><given-names>R</given-names></name><name><surname>Gonzalez Sagrado</surname><given-names>M</given-names></name><name><surname>Primo</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial</article-title>
<source>Eur Rev Med Pharmacol Sci</source>
<year>2011</year>
<volume>15</volume>
<fpage>1090</fpage>
<lpage>1095</lpage>
<pub-id pub-id-type="pmid">22013734</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal">
<person-group><name><surname>Aqel</surname><given-names>B</given-names></name><name><surname>DiBaise</surname><given-names>JK</given-names></name></person-group>
<article-title>Role of the gut microbiome in nonalcoholic fatty liver disease</article-title>
<source>Nutr Clin Pract</source>
<year>2015</year>
<volume>30</volume>
<fpage>780</fpage>
<lpage>786</lpage>
<pub-id pub-id-type="pmid">26449892</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal">
<person-group><name><surname>Baradaran</surname><given-names>A</given-names></name><name><surname>Nasri</surname><given-names>H</given-names></name><name><surname>Rafieian-Kopaei</surname><given-names>M</given-names></name></person-group>
<article-title>Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants</article-title>
<source>J Res Med Sci</source>
<year>2014</year>
<volume>19</volume>
<fpage>358</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="pmid">25097610</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal">
<person-group><name><surname>Boirivant</surname><given-names>M</given-names></name><name><surname>Strober</surname><given-names>W</given-names></name></person-group>
<article-title>The mechanism of action of probiotics</article-title>
<source>Curr Opin Gastroenterol</source>
<year>2007</year>
<volume>23</volume>
<fpage>679</fpage>
<lpage>692</lpage>
<pub-id pub-id-type="pmid">17906447</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal">
<person-group><name><surname>Cassidy</surname><given-names>S</given-names></name><name><surname>Hallsworth</surname><given-names>K</given-names></name><name><surname>Thoma</surname><given-names>C</given-names></name><name><surname>MacGowan</surname><given-names>GA</given-names></name><name><surname>Hollingsworth</surname><given-names>KG</given-names></name><name><surname>Day</surname><given-names>CP</given-names></name><etal/></person-group>
<article-title>Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control</article-title>
<source>Cardiovasc Diabetol</source>
<year>2015</year>
<volume>14</volume>
<fpage>23</fpage>
<pub-id pub-id-type="pmid">25849783</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal">
<person-group><name><surname>Chalasani</surname><given-names>N</given-names></name><name><surname>Younossi</surname><given-names>Z</given-names></name><name><surname>Lavine</surname><given-names>JE</given-names></name><name><surname>Diehl</surname><given-names>AM</given-names></name><name><surname>Brunt</surname><given-names>EM</given-names></name><name><surname>Cusi</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology</article-title>
<source>Gastroenterology</source>
<year>2012</year>
<volume>142</volume>
<fpage>1592</fpage>
<lpage>1609</lpage>
<pub-id pub-id-type="pmid">22656328</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal">
<person-group><name><surname>Chin-Dusting</surname><given-names>JP</given-names></name><name><surname>Rasaratnam</surname><given-names>B</given-names></name><name><surname>Jennings</surname><given-names>GL</given-names></name><name><surname>Dudley</surname><given-names>FJ</given-names></name></person-group>
<article-title>Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis</article-title>
<source>Ann Intern Med</source>
<year>1997</year>
<volume>127</volume>
<fpage>985</fpage>
<lpage>988</lpage>
<pub-id pub-id-type="pmid">9412304</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal">
<person-group><name><surname>Daga</surname><given-names>MK</given-names></name><name><surname>Chhabra</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>B</given-names></name><name><surname>Mishra</surname><given-names>TK</given-names></name></person-group>
<article-title>Effects of exogenous vitamin E supplementation on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease</article-title>
<source>J Biosci</source>
<year>2003</year>
<volume>28</volume>
<fpage>7</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">12682418</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal">
<person-group><name><surname>Ebel</surname><given-names>B</given-names></name><name><surname>Lemetais</surname><given-names>G</given-names></name><name><surname>Beney</surname><given-names>L</given-names></name><name><surname>Cachon</surname><given-names>R</given-names></name><name><surname>Sokol</surname><given-names>H</given-names></name><name><surname>Langella</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Impact of probiotics on risk factors for cardiovascular diseases. A review</article-title>
<source>Crit Rev Food Sci Nutr</source>
<year>2014</year>
<volume>54</volume>
<fpage>175</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="pmid">24188267</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal">
<person-group><name><surname>Ejtahed</surname><given-names>HS</given-names></name><name><surname>Mohtadi-Nia</surname><given-names>J</given-names></name><name><surname>Homayouni-Rad</surname><given-names>A</given-names></name><name><surname>Niafar</surname><given-names>M</given-names></name><name><surname>Asghari-Jafarabadi</surname><given-names>M</given-names></name><name><surname>Mofid</surname><given-names>V</given-names></name></person-group>
<article-title>Probiotic yogurt improves antioxidant status in type 2 diabetic patients</article-title>
<source>Nutrition</source>
<year>2012</year>
<volume>28</volume>
<fpage>539</fpage>
<lpage>543</lpage>
<pub-id pub-id-type="pmid">22129852</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal">
<person-group><name><surname>Frances</surname><given-names>R</given-names></name><name><surname>Munoz</surname><given-names>C</given-names></name><name><surname>Zapater</surname><given-names>P</given-names></name><name><surname>Uceda</surname><given-names>F</given-names></name><name><surname>Gascon</surname><given-names>I</given-names></name><name><surname>Pascual</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites</article-title>
<source>Gut</source>
<year>2004</year>
<volume>53</volume>
<fpage>860</fpage>
<lpage>864</lpage>
<pub-id pub-id-type="pmid">15138214</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal">
<person-group><name><surname>Frances</surname><given-names>R</given-names></name><name><surname>Rodriguez</surname><given-names>E</given-names></name><name><surname>Munoz</surname><given-names>C</given-names></name><name><surname>Zapater</surname><given-names>P</given-names></name><name><surname>De la</surname><given-names>ML</given-names></name><name><surname>Ndongo</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Intracellular cytokine expression in peritoneal monocyte/macrophages obtained from patients with cirrhosis and presence of bacterial DNA</article-title>
<source>Eur J Gastroenterol Hepatol</source>
<year>2005</year>
<volume>17</volume>
<fpage>45</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">15647640</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal">
<person-group><name><surname>Furushiro</surname><given-names>M</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name><name><surname>Hamura</surname><given-names>M</given-names></name><name><surname>Yokokura</surname><given-names>T</given-names></name></person-group>
<article-title>Mechanism for the antihypertensive effect of a polysaccharide-glycopeptide complex from Lactobacillus casei in spontaneously hypertensive rats (SHR)</article-title>
<source>Biosci Biotechnol Biochem</source>
<year>1993</year>
<volume>57</volume>
<fpage>978</fpage>
<lpage>981</lpage>
<pub-id pub-id-type="pmid">7763887</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal">
<person-group><name><surname>Giles</surname><given-names>TD</given-names></name><name><surname>Sander</surname><given-names>GE</given-names></name><name><surname>Nossaman</surname><given-names>BD</given-names></name><name><surname>Kadowitz</surname><given-names>PJ</given-names></name></person-group>
<article-title>Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins</article-title>
<source>J Clin Hypertens</source>
<year>2012</year>
<volume>14</volume>
<fpage>198</fpage>
<lpage>205</lpage>
</element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal">
<person-group><name><surname>Harrison</surname><given-names>SA</given-names></name><name><surname>Torgerson</surname><given-names>S</given-names></name><name><surname>Hayashi</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>J</given-names></name><name><surname>Schenker</surname><given-names>S</given-names></name></person-group>
<article-title>Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis</article-title>
<source>Am J Gastroenterol</source>
<year>2003</year>
<volume>98</volume>
<fpage>2485</fpage>
<lpage>2490</lpage>
<pub-id pub-id-type="pmid">14638353</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal">
<person-group><name><surname>Hollingsworth</surname><given-names>KG</given-names></name><name><surname>Blamire</surname><given-names>AM</given-names></name><name><surname>Keavney</surname><given-names>BD</given-names></name><name><surname>Macgowan</surname><given-names>GA</given-names></name></person-group>
<article-title>Left ventricular torsion, energetics, and diastolic function in normal human aging</article-title>
<source>Am J Physiol Heart Circ Physiol</source>
<year>2012</year>
<volume>302</volume>
<fpage>885</fpage>
<lpage>892</lpage>
</element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal">
<person-group><name><surname>Jamali</surname><given-names>R</given-names></name><name><surname>Khonsari</surname><given-names>M</given-names></name><name><surname>Merat</surname><given-names>S</given-names></name><name><surname>Khoshnia</surname><given-names>M</given-names></name><name><surname>Jafari</surname><given-names>E</given-names></name><name><surname>Bahram Kalhori</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes</article-title>
<source>World J Gastroenterol</source>
<year>2008</year>
<volume>14</volume>
<fpage>2867</fpage>
<lpage>2871</lpage>
<pub-id pub-id-type="pmid">18473412</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal">
<person-group><name><surname>Janero</surname><given-names>DR</given-names></name></person-group>
<article-title>Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury</article-title>
<source>Free Radic Biol Med</source>
<year>1990</year>
<volume>9</volume>
<fpage>515</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="pmid">2079232</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal">
<person-group><name><surname>Lata</surname><given-names>J</given-names></name><name><surname>Novotny</surname><given-names>I</given-names></name><name><surname>Pribramska</surname><given-names>V</given-names></name><name><surname>Jurankova</surname><given-names>J</given-names></name><name><surname>Fric</surname><given-names>P</given-names></name><name><surname>Kroupa</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study</article-title>
<source>Eur J Gastroenterol Hepatol</source>
<year>2007</year>
<volume>19</volume>
<fpage>1111</fpage>
<lpage>1113</lpage>
<pub-id pub-id-type="pmid">17998837</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal">
<person-group><name><surname>Lau</surname><given-names>K</given-names></name><name><surname>Lorbeer</surname><given-names>R</given-names></name><name><surname>Haring</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>CO</given-names></name><name><surname>Wallaschofski</surname><given-names>H</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study</article-title>
<source>J Hypertens</source>
<year>2010</year>
<volume>28</volume>
<fpage>1829</fpage>
<lpage>1835</lpage>
<pub-id pub-id-type="pmid">20577126</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal">
<person-group><name><surname>Lavine</surname><given-names>JE</given-names></name></person-group>
<article-title>Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study</article-title>
<source>J Pediatr</source>
<year>2000</year>
<volume>136</volume>
<fpage>734</fpage>
<lpage>738</lpage>
<pub-id pub-id-type="pmid">10839868</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal">
<person-group><name><surname>Loguercio</surname><given-names>C</given-names></name><name><surname>Federico</surname><given-names>A</given-names></name><name><surname>Tuccillo</surname><given-names>C</given-names></name><name><surname>Terracciano</surname><given-names>F</given-names></name><name><surname>D'Auria</surname><given-names>MV</given-names></name><name><surname>De Simone</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases</article-title>
<source>J Clin Gastroenterol</source>
<year>2005</year>
<volume>39</volume>
<fpage>540</fpage>
<lpage>543</lpage>
<pub-id pub-id-type="pmid">15942443</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal">
<person-group><name><surname>Malaguarnera</surname><given-names>M</given-names></name><name><surname>Vacante</surname><given-names>M</given-names></name><name><surname>Antic</surname><given-names>T</given-names></name><name><surname>Giordano</surname><given-names>M</given-names></name><name><surname>Chisari</surname><given-names>G</given-names></name><name><surname>Acquaviva</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis</article-title>
<source>Dig Dis Sci</source>
<year>2012</year>
<volume>57</volume>
<fpage>545</fpage>
<lpage>553</lpage>
<pub-id pub-id-type="pmid">21901256</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal">
<person-group><name><surname>Medina</surname><given-names>J</given-names></name><name><surname>Fernandez-Salazar</surname><given-names>LI</given-names></name><name><surname>Garcia-Buey</surname><given-names>L</given-names></name><name><surname>Moreno-Otero</surname><given-names>R</given-names></name></person-group>
<article-title>Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis</article-title>
<source>Diabetes Care</source>
<year>2004</year>
<volume>27</volume>
<fpage>2057</fpage>
<lpage>2066</lpage>
<pub-id pub-id-type="pmid">15277442</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal">
<person-group><name><surname>Myhre</surname><given-names>R</given-names></name><name><surname>Brantsaeter</surname><given-names>AL</given-names></name><name><surname>Myking</surname><given-names>S</given-names></name><name><surname>Gjessing</surname><given-names>HK</given-names></name><name><surname>Sengpiel</surname><given-names>V</given-names></name><name><surname>Meltzer</surname><given-names>HM</given-names></name><etal/></person-group>
<article-title>Intake of probiotic food and risk of spontaneous preterm delivery</article-title>
<source>Am J Clin Nutr</source>
<year>2011</year>
<volume>93</volume>
<fpage>151</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="pmid">20980489</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal">
<person-group><name><surname>Peralta</surname><given-names>C</given-names></name><name><surname>Rosello-Catafau</surname><given-names>J</given-names></name></person-group>
<article-title>The future of fatty livers</article-title>
<source>J Hepatol</source>
<year>2004</year>
<volume>41</volume>
<fpage>149</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="pmid">15246222</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal">
<person-group><name><surname>Raij</surname><given-names>L</given-names></name></person-group>
<article-title>Hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction</article-title>
<source>Hypertension</source>
<year>2001</year>
<volume>37</volume>
<fpage>767</fpage>
<lpage>773</lpage>
<pub-id pub-id-type="pmid">11230371</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal">
<person-group><name><surname>Rayes</surname><given-names>N</given-names></name><name><surname>Seehofer</surname><given-names>D</given-names></name><name><surname>Hansen</surname><given-names>S</given-names></name><name><surname>Boucsein</surname><given-names>K</given-names></name><name><surname>Muller</surname><given-names>AR</given-names></name><name><surname>Serke</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients</article-title>
<source>Transplantation</source>
<year>2002</year>
<volume>74</volume>
<fpage>123</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="pmid">12134110</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal">
<person-group><name><surname>Rayes</surname><given-names>N</given-names></name><name><surname>Seehofer</surname><given-names>D</given-names></name><name><surname>Theruvath</surname><given-names>T</given-names></name><name><surname>Schiller</surname><given-names>RA</given-names></name><name><surname>Langrehr</surname><given-names>JM</given-names></name><name><surname>Jonas</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial</article-title>
<source>Am J Transplant</source>
<year>2005</year>
<volume>5</volume>
<fpage>125</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="pmid">15636620</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal">
<person-group><name><surname>Reid</surname><given-names>G</given-names></name><name><surname>Dols</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>W</given-names></name></person-group>
<article-title>Targeting the vaginal microbiota with probiotics as a means to counteract infections</article-title>
<source>Curr Opin Clin Nutr Metab Care</source>
<year>2009</year>
<volume>12</volume>
<fpage>583</fpage>
<lpage>587</lpage>
<pub-id pub-id-type="pmid">19741517</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal">
<person-group><name><surname>Rimola</surname><given-names>A</given-names></name><name><surname>Soto</surname><given-names>R</given-names></name><name><surname>Bory</surname><given-names>F</given-names></name><name><surname>Arroyo</surname><given-names>V</given-names></name><name><surname>Piera</surname><given-names>C</given-names></name><name><surname>Rodes</surname><given-names>J</given-names></name></person-group>
<article-title>Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis</article-title>
<source>Hepatology</source>
<year>1984</year>
<volume>4</volume>
<fpage>53</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">6693068</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal">
<person-group><name><surname>Rodrigo</surname><given-names>R</given-names></name><name><surname>Prat</surname><given-names>H</given-names></name><name><surname>Passalacqua</surname><given-names>W</given-names></name><name><surname>Araya</surname><given-names>J</given-names></name><name><surname>Bachler</surname><given-names>JP</given-names></name></person-group>
<article-title>Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension</article-title>
<source>Clin Sci</source>
<year>2008</year>
<volume>114</volume>
<fpage>625</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="pmid">17999638</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal">
<person-group><name><surname>Sawada</surname><given-names>H</given-names></name><name><surname>Furushiro</surname><given-names>M</given-names></name><name><surname>Hirai</surname><given-names>K</given-names></name><name><surname>Motoike</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Yokokura</surname><given-names>T</given-names></name></person-group>
<article-title>Purification and characterization of an antihypertensive compound from Lactobacillus casei</article-title>
<source>Agric Biol Chem</source>
<year>1990</year>
<volume>54</volume>
<fpage>3211</fpage>
<lpage>3219</lpage>
<pub-id pub-id-type="pmid">1368639</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal">
<person-group><name><surname>Solga</surname><given-names>SF</given-names></name><name><surname>Diehl</surname><given-names>AM</given-names></name></person-group>
<article-title>Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics</article-title>
<source>J Hepatol</source>
<year>2003</year>
<volume>38</volume>
<fpage>681</fpage>
<lpage>687</lpage>
<pub-id pub-id-type="pmid">12713883</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal">
<person-group><name><surname>Tandon</surname><given-names>P</given-names></name><name><surname>Moncrief</surname><given-names>K</given-names></name><name><surname>Madsen</surname><given-names>K</given-names></name><name><surname>Arrieta</surname><given-names>MC</given-names></name><name><surname>Owen</surname><given-names>RJ</given-names></name><name><surname>Bain</surname><given-names>VG</given-names></name><etal/></person-group>
<article-title>Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study</article-title>
<source>Liver Int</source>
<year>2009</year>
<volume>29</volume>
<fpage>1110</fpage>
<lpage>1115</lpage>
<pub-id pub-id-type="pmid">19490420</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal">
<person-group><name><surname>Tatsch</surname><given-names>E</given-names></name><name><surname>Bochi</surname><given-names>GV</given-names></name><name><surname>Pereira Rda</surname><given-names>S</given-names></name><name><surname>Kober</surname><given-names>H</given-names></name><name><surname>Agertt</surname><given-names>VA</given-names></name><name><surname>de Campos</surname><given-names>MM</given-names></name><etal/></person-group>
<article-title>A simple and inexpensive automated technique for measurement of serum nitrite/nitrate</article-title>
<source>Clin Biochem</source>
<year>2011</year>
<volume>44</volume>
<fpage>348</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="pmid">21185277</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal">
<person-group><name><surname>Tilg</surname><given-names>H</given-names></name><name><surname>Diehl</surname><given-names>AM</given-names></name></person-group>
<article-title>Cytokines in alcoholic and nonalcoholic steatohepatitis</article-title>
<source>N Engl J Med</source>
<year>2000</year>
<volume>343</volume>
<fpage>1467</fpage>
<lpage>1476</lpage>
<pub-id pub-id-type="pmid">11078773</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal">
<person-group><name><surname>Vajro</surname><given-names>P</given-names></name><name><surname>Mandato</surname><given-names>C</given-names></name><name><surname>Franzese</surname><given-names>A</given-names></name><name><surname>Ciccimarra</surname><given-names>E</given-names></name><name><surname>Lucariello</surname><given-names>S</given-names></name><name><surname>Savoia</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Vitamin E treatment in pediatric obesity-related liver disease: a randomized study</article-title>
<source>J Pediatr Gastroenterol Nutr</source>
<year>2004</year>
<volume>38</volume>
<fpage>48</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">14676594</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal">
<person-group><name><surname>Vajro</surname><given-names>P</given-names></name><name><surname>Mandato</surname><given-names>C</given-names></name><name><surname>Licenziati</surname><given-names>MR</given-names></name><name><surname>Franzese</surname><given-names>A</given-names></name><name><surname>Vitale</surname><given-names>DF</given-names></name><name><surname>Lenta</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease</article-title>
<source>J Pediatr Gastroenterol Nutr</source>
<year>2011</year>
<volume>52</volume>
<fpage>740</fpage>
<lpage>743</lpage>
<pub-id pub-id-type="pmid">21505361</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal">
<person-group><name><surname>van Baarlen</surname><given-names>P</given-names></name><name><surname>Troost</surname><given-names>F</given-names></name><name><surname>van der Meer</surname><given-names>C</given-names></name><name><surname>Hooiveld</surname><given-names>G</given-names></name><name><surname>Boekschoten</surname><given-names>M</given-names></name><name><surname>Brummer</surname><given-names>RJ</given-names></name><etal/></person-group>
<article-title>Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2011</year>
<volume>108</volume>
<issue>Suppl 1</issue>
<fpage>4562</fpage>
<lpage>4569</lpage>
<pub-id pub-id-type="pmid">20823239</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal">
<person-group><name><surname>Vivekananthan</surname><given-names>DP</given-names></name><name><surname>Penn</surname><given-names>MS</given-names></name><name><surname>Sapp</surname><given-names>SK</given-names></name><name><surname>Hsu</surname><given-names>A</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group>
<article-title>Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials</article-title>
<source>Lancet</source>
<year>2003</year>
<volume>361</volume>
<issue>9374</issue>
<fpage>2017</fpage>
<lpage>2023</lpage>
<pub-id pub-id-type="pmid">12814711</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal">
<person-group><name><surname>Wiest</surname><given-names>R</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Cadelina</surname><given-names>G</given-names></name><name><surname>Garcia-Tsao</surname><given-names>G</given-names></name><name><surname>Milstien</surname><given-names>S</given-names></name><name><surname>Groszmann</surname><given-names>RJ</given-names></name></person-group>
<article-title>Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility</article-title>
<source>J Clin Invest</source>
<year>1999</year>
<volume>104</volume>
<fpage>1223</fpage>
<lpage>1233</lpage>
<pub-id pub-id-type="pmid">10545521</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal">
<person-group><name><surname>Wilkinson</surname><given-names>IB</given-names></name><name><surname>Franklin</surname><given-names>SS</given-names></name><name><surname>Cockcroft</surname><given-names>JR</given-names></name></person-group>
<article-title>Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology</article-title>
<source>Hypertension</source>
<year>2004</year>
<volume>44</volume>
<fpage>112</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="pmid">15262901</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal">
<person-group><name><surname>Wong</surname><given-names>VW</given-names></name><name><surname>Wong</surname><given-names>GL</given-names></name><name><surname>Yeung</surname><given-names>DK</given-names></name><name><surname>Abrigo</surname><given-names>JM</given-names></name><name><surname>Kong</surname><given-names>AP</given-names></name><name><surname>Chan</surname><given-names>RS</given-names></name><etal/></person-group>
<article-title>Fatty pancreas, insulin resistance, and beta-cell function: a population study using fat-water magnetic resonance imaging</article-title>
<source>Am J Gastroenterol</source>
<year>2014</year>
<volume>109</volume>
<fpage>589</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="pmid">24492753</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal">
<person-group><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Akino</surname><given-names>A</given-names></name><name><surname>Takano</surname><given-names>T</given-names></name></person-group>
<article-title>Antihypertensive effect of the peptides derived from casein by an extracellular proteinase from Lactobacillus helveticus CP790</article-title>
<source>J Dairy Sci</source>
<year>1994</year>
<volume>77</volume>
<fpage>917</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="pmid">8201050</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal">
<person-group><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group>
<article-title>The antioxidative effects of probiotic Lactobacillus casei Zhang on the hyperlipidemic rats</article-title>
<source>Eur Food Res Technol</source>
<year>2010</year>
<volume>231</volume>
<fpage>151</fpage>
<lpage>158</lpage>
</element-citation></ref></ref-list></back><floats-group><fig id="T1" position="float"><label>Table 1</label><caption><title>Baseline, end and change values of anthropometric indicators and blood pressure of study participants</title></caption><graphic xlink:href="EXCLI-16-278-t-001"/></fig><fig id="T2" position="float"><label>Table 2</label><caption><title>Dietary intakes of study participants throughout the study</title></caption><graphic xlink:href="EXCLI-16-278-t-002"/></fig><fig id="T3" position="float"><label>Table 3</label><caption><title>Baseline, end and change values of serum liver enzymes and some measured inflammatory factors of study participants</title></caption><graphic xlink:href="EXCLI-16-278-t-003"/></fig><fig id="T4" position="float"><label>Table 4</label><caption><title>Adjusted changes in biochemical measurement and blood pressure in NAFLD patients that received symbiotic plus alpha-tocopherol, symbiotic and alpha-tocopherol supplements or placebo</title></caption><graphic xlink:href="EXCLI-16-278-t-004"/></fig><fig id="F1" position="float"><label>Figure 1</label><caption><title>Flow diagram of patient recruitment and randomization process</title></caption><graphic xlink:href="EXCLI-16-278-g-001"/></fig></floats-group></article>